NASDAQ · FENC
Healthcare · Biotechnology
$10.55
Up+$0.23 (+2.21%)
Updated Sep 17, 2026, 5:30 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
FENC closed at $10.55 after 20 trading sessions, down 11.12% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $10.64 | $10.96 | $10.515 | $10.55 | 170.33K |
| Sep 15, 2026 | $10.60 | $10.65 | $10.135 | $10.64 | 253.7K |
| Sep 14, 2026 | $10.94 | $11.11 | $10.68 | $10.72 | 186.01K |
| Sep 11, 2026 | $11.30 | $11.51 | $10.85 | $10.96 | 249.93K |
| Sep 10, 2026 | $11.51 | $11.7299 | $11.271 | $11.30 | 171.68K |
| Sep 9, 2026 | $12.35 | $12.45 | $11.42 | $11.65 | 348.66K |
| Sep 8, 2026 | $12.16 | $12.53 | $12.0823 | $12.45 | 256.28K |
| Sep 4, 2026 | $12.45 | $12.60 | $12.29 | $12.39 | 212.44K |
| Sep 3, 2026 | $12.42 | $12.79 | $12.13 | $12.55 | 296.1K |
| Sep 2, 2026 | $12.04 | $12.3899 | $11.87 | $12.31 | 292.04K |
| Sep 1, 2026 | $12.35 | $12.4199 | $11.8815 | $12.03 | 348.05K |
| Aug 31, 2026 | $12.29 | $12.685 | $12.075 | $12.35 | 508.68K |
| Aug 28, 2026 | $11.71 | $12.505 | $11.60 | $12.27 | 421.81K |
| Aug 27, 2026 | $12.13 | $12.1928 | $11.61 | $11.77 | 296.83K |
| Aug 26, 2026 | $11.70 | $12.28 | $11.295 | $12.17 | 250.95K |
| Aug 25, 2026 | $11.44 | $11.8799 | $11.44 | $11.71 | 198.35K |
| Aug 24, 2026 | $11.29 | $11.47 | $10.88 | $11.40 | 218.9K |
| Aug 21, 2026 | $11.47 | $11.65 | $11.22 | $11.29 | 210.74K |
| Aug 20, 2026 | $11.79 | $11.9734 | $11.17 | $11.35 | 246.21K |
| Aug 19, 2026 | $12.00 | $12.19 | $11.79 | $11.87 | 165.41K |
The latest Smart Investors Daily articles mentioning FENC.
FENC research
Company profile and research snapshot.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 12, 2026 | Wedbush | Outperform | — |
| Aug 12, 2026 | B. Riley Securities | Buy | — |
| May 22, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 16, 2026 | Wedbush | Outperform | — |
No generated briefing is available yet.
Benzinga · Sep 9, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains $16 price target.
Benzinga · Aug 12, 2026
B. Riley Securities analyst Madison El-Saadi reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $16 to $18.
Benzinga · Aug 12, 2026
Wedbush analyst David Nierengarten maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and raises the price target from $13 to $16.
SeekingAlpha · Aug 12, 2026
Fennec Pharma (FENC) hits near highs on PEDMARK profits, but 36x forward earnings and single-asset risk leave no margin of safety.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FENC.
